24 okt: Novozymes overvejer at appellere tabt patentsag i USA
24 okt: Novo-rival overrasker positivt - diabetesmidler præsterer godt - ..
24-10-2017 12:43:07

U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

Relateret indhold
07 feb - 
Aktier/middag: Lundbeck og Novozymes i top og bund efte..
07 feb - 
Aktier/åbning: Fremgang efter regnskaber fra kvartet af..
07 feb - 
Aktier/tendens: Store regnskaber før åbning med udsigt ..
Relateret debat
09:25 - 
@hanfrank12, modsat dig har jeg forstået, at foku..
09:17 - 
Company announcement - No. 04 / 2018 Zealand Pharma and..
09:14 - 
https://cws.huginonline.com/Z/136974/PR/201802/2170158_..

Company announcement - No. 48/2017

U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare disease short bowel syndrome (SBS)*. Glepaglutide is a Zealand-invented long-acting GLP-2 analog that may offer a treatment option for patients with reduced or complete loss of intestinal function. Glepaglutide has been shown to reduce fecal wet weight output as well as indicated increases in both energy, fluid and electrolyte absorption in SBS patients in a Phase 2 trial. Interactions with U.S. and EU regulatory authorities are planned with the aim of moving glepaglutide into Phase 3 clinical trials in 2018.

Britt Meelby Jensen, President and CEO of Zealand, comments:

"The orphan drug designation is great news, both for Zealand and for the patients suffering from short bowel syndrome. The orphan drug designation for glepaglutide enables us to have a closer and more frequent dialogue with the FDA throughout our late stage clinical development. Glepaglutide is one of Zealand's leading product candidates, which we are developing all the way to market, and this designation is an important step for us in our efforts to ensure an efficient path to registration and patient access."

The United States Congress passed the Orphan Drug Act in 1983 to provide incentives for industry investment in treatments for rare conditions. Companies that receive orphan drug designation for their products qualify for various incentives including tax credits for clinical trial costs, relief from prescription drug user fees and the potential for seven years of market exclusivity after the drug is approved.

Short bowel syndrome

Short bowel syndrome (SBS) is a life-threatening and complex chronic severe condition associated with reduced or complete loss of intestinal function. In adults, the main underlying causes of SBS are major intestinal surgery following Crohn's disease, ischemia, radiation damage and surgery. It is estimated that 20,000-40,000 patients are affected by SBS in the U.S. and Europe. The most severely affected people are dependent on daily parenteral support. This requires them to be connected to infusion lines and pumps, which pose significant restrictions on their ability to engage in daily activities.

For further information, please contact:

Britt Meelby Jensen, President and CEO

Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim as well as a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow us on Twitter @ZealandPharma or LinkedIn.

*https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?

cfgridkey=539216 

48-17_1024 Orphan drug designation US glepaglutide


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 821615.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 feb
ZEAL
Tror lige Zealand har opdateret deres kommende begivenheder. Bliver spændende i 2018   HELE 13 begiv..
7
16 feb
ZEAL
Berlinske Tidende har i dag en artikel med overskriften "Novos superkombi mod diabetes ramt af frans..
7
15 feb
ZEAL
https://npinvestor.dk/node/385452   Zealand Pharma's dasiglucagon Phase 2a results at the 11th Inter..
4
16 feb
ZEAL
Kompliance er fortsat et stort problem inden for medicin generelt. Jo, flere lægemidler du skal beny..
3
16 feb
ZEAL
Nej, det du ikke ved er, at Suliqua kun sælges uden for USA, mens Soliqua sælges i USA.   Her er Sol..
3
17 feb
ZEAL
"Det går endvidere rigtig godt med mine shortpositioner i Novo Nordisk"    Selvfølgelig.    Så dem d..
2
17 feb
ZEAL
Europa Xultophy fakta er også ret tydeleige
2
17 feb
ZEAL
Højeste pris og bedste produkt = Saxenda   62% vækst 40% value markedsandel USA 86% value markedsan..
2
16 feb
ZEAL
Kernen i problemet med mixprodukter er nu endeligt klarlagt af begge producenter:   "Sanofi har tidl..
2
16 feb
ZEAL
Nej det gjorde jeg ikke !   Dengang var jeg flink, at medtage hele Sanofi/Zealands markedsandel på 0..
2

Aktier/middag: Mærsk trækker C25 i rødt med nyt fra kapitalmarkedsdag

20-02-2018 11:42:02
De danske eliteaktier er delt nogenlunde på midten tirsdag formiddag, men Mærsk-aktierne agerer tunge lodder i bunden, som trækker det samlede C25-indeks ned i et mindre fald på 0,5 pct. til 1126,09.Mærsk holder kapitalmarkedsdag tirsdag i København, og de oplysninger, der indtil nu er sluppet ud fra Operaen, har tilsyneladende ikke opmuntret investorerne, der sender Mærsk-aktierne ned.Generelt er..

KORR: Novo/Kepler: Hæver kursmål og fastholder "hold"

20-02-2018 07:35:49
(Slutkursen på Novo-aktien rettet, red.)Det schweiziske finanshus Kepler Cheuvreux hæver kursmålet for en aktie i Novo Nordisk til 273 kr. fra tidligere 256 kr. I samme omgang fastholdes anbefalingen på "hold".Det fremgår af data fra Bloomberg News.En aktie i Novo Nordisk kostede 308,05 kr. efter et fald på 1,7 pct. mandag./ritzau/FINANSCharlotte Mackeprang +45 33 30 03 61 Ritzau Finans, E-mail:fi..

WDH OPTAKT H2 22/2: Oticon Opn-maskinen skal til eftersyn

19-02-2018 15:42:01
Det helt store spørgsmål på de fleste investorers blokke inden årsregnskabet for 2017 fra William Demant Holding er formentlig, om det trådløse topprodukt inden for høreapparater, Oticon Opn, har kunnet fortsætte med at bidrage til stærk vækst og indtjening i andet halvår.Produktet blev lanceret for godt halvandet år siden og er derfor relativt langt henne i den normale livscyklus for høreapparate..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank foreslår topchefernes skræk til bestyrelsen
2
Regeringen: Kommission skal tjekke udbytteskat
3
Mandagens aktier: Defensiv nedtur for C25 trods plusser til Mærsk
4
KORR: Novo/Kepler: Hæver kursmål og fastholder "hold"
5
Aktier/åbning: Mærsk tager vand ind mens strategien præsenteres

Relaterede aktiekurser

Zealand Pharma A/S 91,50 0,5% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. februar 2018 14:41:16
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180219.1 - EUROWEB5 - 2018-02-20 14:41:16 - 2018-02-20 14:41:16 - 1 - Website: OKAY